Insulet Corporation

▲ Bull Case

• ◆T2D penetration accelerates to 10%+ of eligible patients, expanding the addressable market 3–5× beyond T1D; International revenue exceeds 40% of total by FY2028; FCF margin reaches 22–24%; 30x FY2028E FCF of ~$950M implies a price of ~$270 (+80% from $150).
• ◆T1D is 100% immune to GLP-1 drugs, protecting ~73% of the current customer base unconditionally; T1D pump penetration at only 20% leaves 80% of eligible patients still on injections — a 15-year runway even without any T2D contribution.
• ◆Malaysia manufacturing scale drives gross margin expansion from 71.6% to 76%+ by FY2028, amplifying FCF growth well above revenue growth; each 1,000 new customers adds $2–4M/yr in recurring FCF, creating a compounding flywheel that reaches $900M FCF by FY2028E — a 33%+ CAGR requiring no extraordinary assumptions beyond guidance execution.

▼ Bear Case

• ◆US Omnipod growth decelerates to below 12% as T1D market saturates faster than the T2D commercial ramp can compensate, while Medtronic 780G captures ~30% of new T2D AID prescriptions; FCF stalls at $460–500M and the stock re-rates to ~$137 (-8.7% from $150).
• ◆A peer-reviewed RCT confirms GLP-1 drugs reduce long-run T2D insulin dependency by more than 20%, structurally reducing the T2D addressable market PODD is penetrating and validating the bear thesis that GLP-1 and insulin pumps are competitors rather than complements.
• ◆CEO McEvoy, less than 12 months into tenure, stumbles in executing the T2D commercial strategy; FY2026 guidance is missed by more than 10% on both revenue and FCF simultaneously, breaking the conservative guidance culture that has underpinned 5-of-6 consecutive beats and damaging investor trust in the management team.

“The central Wall Street debate is whether GLP-1 drugs represent a permanent structural threat to PODD's addressable market or merely a sentiment-driven overhang with manageable fundamental impact. Bears argue GLP-1 adoption will reduce T2D insulin dependency, shrinking the TAM PODD is counting on for its next growth leg, while US Omnipod growth deceleration (18% in Q1 2026 vs. 31% FY2025) signals T1D saturation is arriving before T2D can compensate. Bulls counter that T1D is biologically immune to GLP-1 drugs (protecting 73% of the base), real-world GLP-1 adherence is only ~50% at 12 months, T2D is a progressive disease where insulin dependency often continues even with GLP-1 use, and combination GLP-1 + pump therapy is emerging as best practice for complex T2D. The secondary debate concerns CEO McEvoy's ability to replicate PODD's conservative guidance culture and execute the T2D prescriber relationship strategy, given his tenure is less than 12 months old. The market prices PODD at 19.6x FY2026E FCF — essentially zero credit for T2D penetration reaching even 10% of eligible patients — suggesting GLP-1 fear and US deceleration are being treated as permanent structural impairments rather than a transitional sentiment trough.”

• ◆Q2 FY2026 earnings (~July 2026): US Omnipod stabilization signal — confirmation that 18% Q1 growth reflects T1D maturation rather than competitive share loss, and early T2D prescription momentum data
• ◆Q3/Q4 FY2026 US T2D prescription data: First full annual T2D commercial data — the single most important near-term thesis validation point for the decade-long T2D growth call option
• ◆International growth sustainability: Continued confirmation of +59.4% Q1 2026 International trajectory across the 9 new markets added in 2025; European T2D reimbursement expansion announcements
• ◆Gross margin reaching 73% full-year FY2026: Validation of Malaysia manufacturing scale thesis and the FCF compounding flywheel
• ◆GLP-1 long-term outcomes data (continuous): Major peer-reviewed studies on T2D insulin dependency at 24+ months — if results confirm combination therapy as best practice, re-rates GLP-1 overhang as sentiment rather than structural
• ◆$600M convertible note refinancing terms (FY2026): Favorable refinancing would strengthen the balance sheet narrative and remove a near-term uncertainty overhang

• ◆GLP-1 drugs structurally reduce T2D insulin dependency beyond the modeled -5–15%, shrinking PODD's TAM expansion runway and validating the bear thesis at a fundamental rather than sentiment level
• ◆US Omnipod growth decelerates below 10% for multiple quarters as T1D market saturates faster than T2D prescriber adoption ramps, exposing the thesis to a structural US plateau
• ◆Medtronic 780G captures more than 30% of new T2D AID prescriptions in the US, leveraging its established endocrinologist relationships and superior TIR clinical data to tilt prescriber preference
• ◆CEO McEvoy fails to replicate PODD's conservative guidance culture or execute the T2D commercial strategy effectively in his first full year, producing a guidance miss >10% on both revenue and FCF simultaneously
• ◆Gross margin expansion stalls below 73% full-year FY2026 due to manufacturing ramp delays, mix shift, input cost inflation, or adverse FX — undermining the highest-conviction demand-independent thesis driver
• ◆CMS reimbursement policy change freezes or reduces T2D insulin pump coverage in the US, eliminating the addressable market before meaningful penetration is achieved (severe case component)